Neoadjuvant Immune Checkpoint Inhibitors in Early Breast Cancer

Дата публикации: 01-10-2024 00:00:00

This meta-analysis examines the efficacy outcomes and safety profile of immune checkpoint inhibitors in combination with adjuvant chemotherapy in patients with early breast cancer across molecular phenotypes.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Cardiotoxicity of Immune Checkpoint Inhibitors	0	8	01-10-2024
2	Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy	0	11.16	01-06-2024
3	Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors	0	4.57	01-09-2023
4	Circulating Tumor DNA in Early Breast Cancer	0	9.02	01-07-2026
5	Immune Checkpoint Inhibitors for Child-Pugh B Hepatocellular Carcinoma	0	11.22	01-10-2023
6	PARP Inhibitors for Breast Cancer Treatment	0	5.63	01-05-2024
7	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
8	PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review	0	8.34	16-07-2026
9	Troponin Screening and Major Cardiovascular Adverse Events During ICI Therapy	0	7.02	21-07-2026
10	Magnetic Resonance Imaging in Prostate Cancer Screening	0	9.31	01-06-2024

Классификация: Мнения. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7.64. Источник: archderm.jamanetwork.com.